Neuropace Inc (NPCE) Stock Price, Quote & News

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data m...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 237 2700

Fax: 650 237 2701

Website: www.neuropace.com

Address:

455 North Bernardo Avenue, Mountain View, United States

Scoops1212 Nov. 12 at 2:05 PM

$NPCE The big question is what does this company have to do financially, to beat their opening price over 4 years ago? They’ve had strong quarterly’s all but once, and they had never reached $20. What da?!

0 · Reply

Joby099 Nov. 7 at 2:03 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

Joby099 Nov. 7 at 2:21 AM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

Joby099 Nov. 6 at 8:37 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

Scoops1212 Nov. 6 at 5:07 PM

$NPCE It would have been very nice to see another big push this morning at the price we opened at.

0 · Reply

Joby099 Nov. 6 at 1:18 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

topstockalerts Nov. 5 at 9:46 PM

Top Gainers PT2 $SONN $LNAI $SORA $NPCE $LMND

0 · Reply

topstockalerts Nov. 5 at 8:58 PM

Top Gainers PT2 $SMX $SORA $NPCE $BW $LMND

0 · Reply

JarvisFlow Nov. 5 at 7:37 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 18.

0 · Reply

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 10 days ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 22, 2025, 8:00 AM EDT - 24 days ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Aug 28, 2025, 8:00 AM EDT - 2 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 12, 2025, 9:50 PM EDT - 3 months ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 3 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 1, 2025, 7:30 AM EDT - 3 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Jun 24, 2025, 4:05 PM EDT - 5 months ago

NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 3:42 AM EDT - 5 months ago

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Jun 13, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Jun 11, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 5 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 5 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Jun 6, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

Jun 4, 2025, 4:09 PM EDT - 5 months ago

NeuroPace Secures Up to $75 Million in Debt Financing

Jun 3, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Jun 2, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

Jun 1, 2025, 10:00 AM EDT - 5 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 12:45 PM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

May 27, 2025, 12:48 PM EDT - 6 months ago

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

May 27, 2025, 8:00 AM EDT - 6 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 13, 2025, 10:33 PM EDT - 6 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 6 months ago

NeuroPace Reports First Quarter 2025 Financial Results

Apr 14, 2025, 4:05 PM EDT - 7 months ago

NeuroPace Provides Update on Tariff Status

Apr 8, 2025, 8:00 AM EDT - 7 months ago

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Apr 3, 2025, 8:00 AM EDT - 8 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Apr 2, 2025, 4:05 PM EDT - 8 months ago

NeuroPace Announces Refocusing of Product Portfolio

Mar 26, 2025, 8:00 AM EDT - 8 months ago

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 4, 2025, 7:45 PM EST - 9 months ago

NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 9 months ago

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 9:15 PM EST - 9 months ago

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 9 months ago

NeuroPace to Present at the Leerink Partners Global Healthcare Conference

Feb 20, 2025, 4:05 PM EST - 9 months ago

NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.

Feb 19, 2025, 4:05 PM EST - 9 months ago

NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Scoops1212 Nov. 12 at 2:05 PM

0 · Reply

Joby099 Nov. 7 at 2:03 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

Joby099 Nov. 7 at 2:21 AM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

Joby099 Nov. 6 at 8:37 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

Scoops1212 Nov. 6 at 5:07 PM

$NPCE It would have been very nice to see another big push this morning at the price we opened at.

0 · Reply

Joby099 Nov. 6 at 1:18 PM

$PLRZ $RIGL $NPCE $LITE

0 · Reply

topstockalerts Nov. 5 at 9:46 PM

Top Gainers PT2 $SONN $LNAI $SORA $NPCE $LMND

0 · Reply

topstockalerts Nov. 5 at 8:58 PM

Top Gainers PT2 $SMX $SORA $NPCE $BW $LMND

0 · Reply

JarvisFlow Nov. 5 at 7:37 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 18.

0 · Reply

stockwitsuser2449 Nov. 5 at 7:31 PM

$NPCE giving up on those earlier gains at the moment, no volume

0 · Reply

stockwitsuser2449 Nov. 5 at 6:32 PM

$NPCE nice runs. those puts are cheap to :)

0 · Reply

topstockalerts Nov. 5 at 4:01 PM

$NPCE It wants to move higher..

0 · Reply

IsabellaDC Nov. 5 at 3:48 PM

Movers over a dollar: $SLDP $SORA $EVC $APPS $NPCE and so on.

0 · Reply

topstockalerts Nov. 5 at 3:36 PM

Top Gainers PT2 $SORA $RIGL $NPCE $KW $EVC

0 · Reply

JarvisFlow Nov. 5 at 3:16 PM

Wells Fargo updates rating for NeuroPace ( $NPCE ) to Overweight, target set at 15 → 16.

0 · Reply

Jonjon1234 Nov. 5 at 2:55 PM

$NPCE Early innings

0 · Reply

Joby099 Nov. 5 at 1:45 PM

$PLRZ $RIGL $NPCE $LITE Great! This ones on my watchlists also. LETSGO! https://www.youtube.com/watch?v=luBgQGU2e8U

0 · Reply

Kaputt Nov. 5 at 1:13 PM

$NPCE Honey, you did it great this time, and i will correspond while doing my best. I’m on the way to the parents house to take the grandma’s wedding ring.

0 · Reply

d_risk Nov. 4 at 10:35 PM

$NPCE - Neuropace Inc. Common Stock - 10Q - Updated Risk Factors NPCE’s risk factors now detail heightened FDA and global regulatory hurdles, stricter compliance and reporting, expanded privacy and cybersecurity threats, new IP and NOL utilization risks, increased exposure to cost-control laws, potential for operating losses and dilution, and greater vulnerability to economic, supply chain, and agency disruptions. #MedicalDevices #SupplyChainDisruptions #IntellectualProperty #CybersecurityRisks #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/NPCE/10-Q/2025-11-04

0 · Reply

topstockalerts Nov. 4 at 9:56 PM

After Hours Top Gainers $ZDAI $NPCE $APPS $SMCZ $CMBM

0 · Reply

TradeMark79 Nov. 4 at 9:44 PM

$NPCE ….👀

0 · Reply

Market Cap	426.68M
Revenue (ttm)	79.91M
Net Income (ttm)	-27.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-33.96%
Debt to Equity Ratio	3.17

Volume	146,000
Avg Vol	182,398
Day's Range	N/A - N/A
Shares Out	33.31M
Stochastic %K	81%
Beta	1.90
Analysts	Strong Sell
Price Target	$17.50